U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937476) titled 'Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole' on April 20.
Brief Summary: This randomized, single-blind (assessor-blind) controlled trial aims to investigate the efficacy of aripiprazole as an augmentation strategy for treating pathological rumination in patients with major depressive disorder (MDD). Pathological rumination-defined as repetitive, intrusive, and uncontrollable negative thinking-has been identified as a major transdiagnostic risk factor for the development, maintenance, and recurrence of depression. Even during clinical remission, ruminative symptoms often persist and strongly pre...